Source:http://linkedlifedata.com/resource/pubmed/id/21730820
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
2011-7-14
|
| pubmed:abstractText |
PAX2 plays an important role in kidney development; although small studies have demonstrated PAX2 expression in Wilms tumors (WT), comprehensive studies on formalin-fixed tissue are lacking. Thus, we systematically evaluated PAX2 immunohistochemical staining in a retrospective study of pediatric WT, as compared with other pediatric tumors. We stained formalin-fixed, paraffin-embedded sections from 39 WT, 6 nephrogenic rests, 8 non-Wilms renal tumors, and 43 nonrenal pediatric small round cell tumors with 2 different PAX2 polyclonal antibodies. PAX2 demonstrated strong, diffuse staining of epithelial and blastema components of WT (97% of cases). PAX2 stained WT stroma in fewer cases (23%), but 80% of anaplastic foci were positive. Nephrogenic rests, 1 case of metanephric adenoma, and 1 pediatric renal cell carcinoma were also PAX2 positive; other pediatric renal tumors were negative. Neuroblastoma, primitive neuroectodermal tumor/Ewings, and T-cell acute lymphoblastic lymphoma (ALL) were PAX2 negative. However, PAX2 weakly stained some cases of B-cell ALL rhabdomyosarcoma (RMS) was also stained, especially alveolar RMS (83%), with less staining of embryonal RMS (13%). One of the antibodies also stained maturing myoid cytoplasm of WT and RMS. This study shows that PAX2 is a sensitive marker of WT (sensitivity 97%), but PAX2 shows weak-to-moderate-intensity nuclear staining of RMS and B-cell ALL, somewhat limiting its utility. However, PAX2 may be a helpful marker in certain diagnostic situations. We speculate that RMS and B-cell ALL staining could be due to antibody cross-reactivity with PAX family members with known expression in RMS and B-cell ALL.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
1532-0979
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
35
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1186-94
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:21730820-Adolescent,
pubmed-meshheading:21730820-Bone Neoplasms,
pubmed-meshheading:21730820-Brain Neoplasms,
pubmed-meshheading:21730820-Child,
pubmed-meshheading:21730820-Child, Preschool,
pubmed-meshheading:21730820-Epithelial Cells,
pubmed-meshheading:21730820-Humans,
pubmed-meshheading:21730820-Immunohistochemistry,
pubmed-meshheading:21730820-Kidney Neoplasms,
pubmed-meshheading:21730820-Neuroblastoma,
pubmed-meshheading:21730820-Neuroectodermal Tumors, Primitive,
pubmed-meshheading:21730820-PAX2 Transcription Factor,
pubmed-meshheading:21730820-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:21730820-Predictive Value of Tests,
pubmed-meshheading:21730820-Retrospective Studies,
pubmed-meshheading:21730820-Rhabdomyosarcoma,
pubmed-meshheading:21730820-Sarcoma, Ewing,
pubmed-meshheading:21730820-Stromal Cells,
pubmed-meshheading:21730820-Tumor Markers, Biological,
pubmed-meshheading:21730820-Wilms Tumor
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
PAX2 expression in Wilms tumors and other childhood neoplasms.
|
| pubmed:affiliation |
Department of Pathology, Oregon Health & Science University, Portland, OR 97239-3098, USA.
|
| pubmed:publicationType |
Journal Article
|